Volume 5, Number 6—December 1999
Dispatch
Effectiveness of Pneumococcal Polysaccharide Vaccine for Preschool-Age Children with Chronic Disease
Anthony E. Fiore
, Orin S. Levine, John A. Elliott, Richard R. Facklam, Jay C. Butler, and for the Pneumococcal Sentinel Surveillance Working Group
, Orin S. Levine, John A. Elliott, Richard R. Facklam, Jay C. Butler, and for the Pneumococcal Sentinel Surveillance Working Group
Table
Estimates of pneumococcal polysaccharide vaccine effectiveness among 173 children 2 through 5 years of age, using the indirect cohort method
| Vaccine serotype/total(%) | |||
|---|---|---|---|
| Group | Vaccinated childrena | Unvaccinated childrena | Effectiveness (95% CI)b |
| All children | 35/48 (73) | 110/125 (88) | 63% (8% to 85%) |
| Children with SCD | 27/33 (82) | 12/13 (92) | 62% (-294% to 98%) |
| Children without SCD | 8/15 (53) | 98/112 (88) | 84% (40% to 96%) |
| Nonconjugate vaccine serotypec | 1/14 (7) | 18/33 (55) | 93% (45% to 100%) |
a23-valent pneumococcal polysaccharide vaccine.
bEffectiveness (95% confidence interval) estimated as (1- odds ratio or 95% confidence bound) x 100%.
cChildren infected with a serotype not in proposed conjugate vaccine (15) (excludes children infected with serotypes 4, 6B, 9V, 14, 18C, 19F, 23F).
SCD, sickle-cell disease.
Page created: December 16, 2010
Page updated: December 16, 2010
Page reviewed: December 16, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.